Recent developments in our understanding of melanocortin system in the regulation of food intake

Obesity Reviews

Volumn 4, Issue 4, 2003, Pages 239-248

  Yang, Y K ^a   Harmon, C M ^a  

^a Kentucky   (United States)

Author keywords

Agouti; AGRP; MSH; Obesity; POMC

Indexed keywords

AGOUTI RELATED PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MELANOCORTIN; SYNDECAN;

CALORIC INTAKE; CENTRAL NERVOUS SYSTEM; ENERGY EXPENDITURE; ENVIRONMENTAL FACTOR; FOOD INTAKE; HUMAN; MOLECULAR BIOLOGY; OBESITY; PATHOGENESIS; PUBLIC HEALTH SERVICE; REVIEW; SIGNAL TRANSDUCTION;

APPETITE REGULATION; EATING; ENERGY INTAKE; ENERGY METABOLISM; HUMANS; HYPOTHALAMUS; MELANOCYTE-STIMULATING HORMONES; OBESITY; PRO-OPIOMELANOCORTIN; RECEPTORS, MELANOCORTIN;

EID: 0344825812     PISSN: 14677881     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1467-789X.2003.00104.x     Document Type: Review

References (129)

1. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA 1999; 282: 1530-1538.
2. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
3. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999; 282: 1519-1522.
4. Butler AA, Cone RD. The melanocortin receptors: lessons from knockout models. Neuropeptides 2002; 36: 77-84.
5. Benoit SC, Schwartz MW, Lachey JL, Hagan MM, Rushing PA, Blake KA, Yagaloff KA, Kurylko G, Franco L, Danhoo W, Seeley RJ. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J Neurosci 2000; 20: 3442-3448.
6. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994; 8: 1298-1308.
7. Abbott CR, Rossi M, Kim MAI, Ahmed SH, Taylor GM, Ghatei MA, Smith DM, Bloom SR. Investigation of the melanocyte stimulating hormones on food intake. Lake of evidence to support a role for the melanocortin-3 receptor. Brain Res 2000; 869: 203-210.
8. Pritchard LE, Turnbull AV, White A. Pro-opiomelanocortin processing in the hypothalamus, impact on melanocortin signalling and obesity. J Endocrinol 2002 March; 172: 411-421.
9. Adan RA, Cone RD, Burbach JP, Gispen WH. Differential effects of melanocortin peptide ligands on neural melanocortin receptors. Mol Pharmacol 1994; 46: 1182-1190.
10. Wirth MM, Giraudo SQ. Agouti-related protein in the hypothalamic paraventricular nucleus: effect on feeding. Peptides 2000; 21: 1369-1375.
11. Gunn TM, Miller KA, He L, Hyman RW, Davis RW, Azarani A, Schlossman SF, Duke-Cohan JS, Barsh GS. The mouse mahogany locus encodes a transmembrane form of human attractin. Nature 1999; 398: 152-156.
12. Miller KA, Gunn TM, Carrasquillo MM, Lamoreux ML, Galbraith DB, Barsh GS. Genetic studies of the mouse mutations mahogany and mahoganoid. Genetics 1997; 146: 1407-1415.
13. Jackson IJ. The mahogany mouse mutation: further links between pigmentation, obesity and the immune system. Trends Genet 1999; 15: 429-431.
14. Strauss E. Fresh molecule whets appetite. Science 2001; 293: 190.
15. Bertagna X. Proopiomelanocortin-derived peptides. Endocrinol Metab Clin North Am 1994; 23: 467-485.
16. Castro MG, Morrison E. Post-translational processing of proopiomelanocortin in the pituitary and in the brain. Crit Rev Neurobiol 1997; 11: 35-57.
17. Smith EM, Blalock JE. Human lymphocyte production of corticotropin and endorphin-like substances: association with leukocyte interferon. Proc Natl Acad Sci USA 1981; 78: 7530-7534.
18. Bloomquist BT, Eipper BA, Mains RE. Prohormone-converting enzymes: regulation and evaluation of function using antisense RNA. Mol Endocrinol 1991; 5: 2014-2024.
19. Zhou A, Bloomquist BT, Mains RE. The prohormone convertases PC1 and PC2 mediate distinct endoproteolytic cleavages in a strict temporal order during proopiomelanocortin biosynthetic processing. J Biol Chem 1993; 268: 1763-1769.
20. Pritchard LE, Oliver RL, McLoughlin JD, Birtles S, Lawrence CB, Turnbull AV, White A. Proopiomelanocortin-derived peptides in rat cerebrospinal fluid and hypothalamic extracts: evidence that secretion is regulated with respect to energy balance. Endocrinology 2003; 144: 760-766.
21. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 1998; 83: 3339-3345.
22. Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos GP, Hochberg Z. Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab 2003; 88: 385-393.
23. Boston BA. The role of melanocortins in adipocyte function. Ann N Y Acad Sci 1999; 20: 75-84.
24. Naggert JK, Fricker LD, Varlamov O, Nishina PM, Rouille Y, Steiner DF, Carroll RJ, Paigen BJ, Leiter EH. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 1995; 10: 135-142.
25. Sturm RA. Skin colour and skin cancer - MC1R, the genetic link. Melanoma Res 2002; 12: 405-416.
26. Abdel-Malek Z, Suzuki I, Tada A, Im S, Akcali C. The melanocortin-1 receptor and human pigmentation. Ann N Y Acad Sci 1999; 885: 117-133.
27. Ste Marie L, Miura GI, Marsh DJ, Yagaloff K, Palmiter RD. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci USA 2000; 97: 12339-12344.
28. De Wied D, Croiset G. Stress modulation of learning and memory processes. Meth Archieve Exp Pathol 1991; 15: 167-199.
29. Luger TA, Kalden D, Scholzen TE, Brzoska T. alpha-Melanocyte-stimulating hormone as a mediator of tolerance induction. Pathobiology 1999; 67: 318-321.
30. Tatro JB. Receptor biology of the melanocortins, a family of neuroimmuno-modulatory peptides. Neuroimmunomodulation 1996; 3: 259-284.
31. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000; 56: 641-646.
32. Opp MR, Obal F Jr, Krueger JM. Effects of alpha-MSH on sleep, behavior, and brain temperature: interactions with IL 1. Am J Physiol 1988; 255: R914-R922.
33. Versteeg DH, Van Bergen P, Adan RA, De Wildt DJ. Melanocortins and cardiovascular regulation. European J Pharmacol 1998; 360: 1-14.
34. Van Bergen P, Janssen PM, Hoogerhout P, De Wildt DJ, Versteeg DH. Cardiovascular effects of gamma-MSH/ACTH-like peptides: structure-activity relationship. Eur J Pharmacol 1995; 294: 795-803.
35. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000; 56: 641-646.
36. Axelrod J, Reisine TD. Stress hormones: their interaction and regulation. Science 1984; 224: 452-459.
37. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19: 155-157.
38. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, O'Rahilly S. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997; 16: 303-306.
39. Zemel MB, Shi H. Pro-opiomelanocortin (POMC) deficiency and peripheral melanocortins in obesity. Nutr Rev 2000; 58: 177-180.
40. Krude H, Gruters A. Implications of proopiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome. Trends Endocrinol Metab 2000; 11: 15-22.
41. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999; 5: 1066-1070.
42. Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaloff KA, Fisher SL, Burn P, Palmiter RD. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 1999; 21: 119-122.
43. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980; 77: 5754-5758.
44. Sawyer TK, Hruby VJ, Darman PS, Hadley ME. [half-Cys4,half-Cys10]-alpha-melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity. Proc Natl Acad Sci USA 1982; 79: 1751-1755.
45. Hruby VJ, Lu D, Sharma SD, Castrucci AL, Kesterson RA, al-Obeidi FA, Hadley ME, Cone RD. Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem 1995; 38: 3454-3461.
46. Schioth HB, Mutulis F, Muceniece R, Prusis P, Wikberg JES. Discovery of novel melanocortin 4 receptor selective MSH analogues. Br J Pharmacol 1998; 124: 75-82.
47. Schioth HB, Muceniece R, Mutulis F, Bouifrouri AA, Mutule I, Wikberg JE. Further pharmacological characterization of the selective melanocortin 4 receptor antagonist HS014: comparison with SHU9119. Neuropeptides 1999; 33: 191-196.
48. Schioth HB, Muceniece R, Mutulis F, Prusis P, Lindeberg G, Sharma SD, Hruby VJ, Wikberg JE. Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH analogues for the melanocortin receptor subtypes. Peptides 1997; 18: 1009-1013.
49. Kask A, Mutulis F, Muceniece R, Pahkla R, Mutule I, Wikberg JE, Rago L, Schioth HB. Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. Endocrinology 1998; 139: 5006-5014.
50. Arasasingham PN, Fotsch C, Ouyang XH, Norman MH, Kelly MG, Stark KL, Karbon B, Hale C, Baumgartner JW, Zambrano M, Cheetham J, Tamayo NA. Structure-activity relationship of (1-Aryl-2-piperazinylethyl) piperazines: antagonists for the AGRP/Melanocortin receptor binding. J Med Chem 2003; 46: 9-11.
51. Sebhat IK, Martin WJ, Ye ZX, Barakat K, Mosley RT, Johnston DBR, Baskshi R, Palucki B, Weinberg DH, MacNeil T, Kalyani RN, Tang R, Stearns RA, Miller RR, Tamvakopoulos C, Strack AM, MacGowan E, Cashen DE, Drisko JE, Hom GJ, Howard AD, MacIntyre DE, van der Ploeg LHT, Patchett AA, Nargund RP. Design and pharmacology of N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl) -2-[4-cyclohexyl-4(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem 2002; 45: 4589-4593.
52. Pan K, Scott MK, Lee DH, Fitzpatrick LJ, Crooke JJ, Rivero RA, Rosenthal DI, Vaidya AH, Zhao B, Reitz AB. 2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats. Bioorg Med Chem 2003; 11: 185-192.
53. Chaki S, Hirota S, Funakoshi T, Suzuki Y, Suetake S, Okubo T, Ishii T, Nakazato A. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl] -4[4-(2-methoxynaphthalen-1-yl)butyl] piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J Pharmacol Exp Ther 2003; 304: 818-826.
54. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 1992; 257: 1248-1251.
55. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, De Watson SJI, Valle J, Yamada T. Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993; 268: 8246-8250.
56. Chhajlani V, Wikberg JE. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett 1992; 309: 417-420.
57. Schioth HB, Chhajlani V, Muceniece R, Klusa V, Wikberg JE. Major pharmacological distinction of the ACTH receptor from other melanocortin receptors. Life Sci 1996; 59: 797-801.
58. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, De Watson SJI, Valle J, Yamada T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993; 268: 15174-15179.
59. Ebihara K, Ogawa Y, Katsuura G, Numata Y, Masuzaki H, Satoh N, Tamaki M, Yoshioka T, Hayase M, Matsuoka N, Aizawa-Abe M, Yoshimasa Y, Nakao K. Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes 1999; 48: 2028-2033.
60. Nijenhuis WA, Oosterom J, Adan RA. AGRP (83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol Endocrinol 2001; 15: 164-171.
61. Adan RA, Szklarczyk AW, Oosterom J, Brakkee JH, Nijenhuis WA, Schaaper WM, Meloen RH, Gispen WH. Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur J Pharmacol 1999; 378: 249-258.
62. Gantz I, Shimoto Y, Konda Y, Dickinson C, Yamada T. Molecular cloning, expression, and characterization of a fifth melanocortin receptor. Bioche Biophy Res Comm 1994; 200: 1214-1220.
63. Schallreuter KU. A review of recent advances on the regulation of pigmentation in the human epidermis. Cell Mol Biol 1999; 45: 943-949.
64. Taherzadeh S, Sharma S, Chhajlani V, Gantz I, Rajora N, Demitri MT, Kelly L, Zhao H, Ichiyama T, Catania A, Lipton JM. α-MSH and its receptors in regulation of tumor necrosis factor-alpha production by human monocyte/macrophages. Am J Physiol 1999; 276: R1289-R1294
65. Morimoto C, Sumiyoshi M, Kameda K, Tsujita T, Okuda H. Relationship between hormone-sensitive lipolysis and lipase activity in rat fat cells. J Biochem 1999; 125: 976-981.
66. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997; 385: 165-168.
67. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88: 131-141.
68. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, Min W, Fisher J, Gopal-Truter S, MacIntyre DE, Chen HY, Van der Ploeg LH. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000; 26: 97-102.
69. Shriver MD, Parra EJ, Dios S, Bonilla C, Norton H, Jovel C, Pfaff C, Jones C, Massac A, Cameron N, Baron A, Jackson T, Argyropoulos G, Jin L, Hoggart CJ, McKeigue PM, Kittles RA. Skin pigmentation, biogeographical ancestry and admixture mapping. Hum Genet 2003; 11: 11.
70. Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ, Cone RD. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997; 91: 789-798.
71. VanLeeuwen D, Steffey ME, Donahue C, Ho G, MacKenzie RG. Cell surface expression of the melanocortin-4 receptor is dependent on a C-terminal di-isoleucine sequence at codons 316/317. J Biol Chem 2003; 278: 15935-15940.
72. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly SA. Frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 1998; 20: 111-112.
73. Gu W, Tu Z, Kleyn PW, Kissebah A, Duprat L, Lee J, Chin W, Maruti S, Deng N, Fisher SL, Franco LS, Burn P, Yagaloff KA, Nathan J, Heymsfield S, Albu J, Pi-Sunyer FX, Allison DB. Identification and functional analysis of novel human melanocortin-4 receptor variants. Diabetes 1999; 48: 635-639.
74. Hinney A, Schmidt A, Nottebom K, Heibult O, Becker I, Ziegler A, Gerber G, Sina M, Gorg T, Mayer H, Siegfried W, Fichter M, Remschmidt H, Hebebrand J. Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J Clin Endocrinol Metab 1999; 84: 1483-1486.
75. Vaisse C, Clement K, Guy-Grand B, Froguel PA. frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 1998; 20: 113-114.
76. Yeo GS, Lank EJ, Farooqi IS, Keogh J, Challis BG, O'Rahilly S. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet 2003; 12: 561-574.
77. Lubrano-Berthelier C, Durand E, Dubern B, Shapiro A, Dazin P, Weill J, Ferron C, Froguel P, Vaisse C. Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet 2003; 12: 145-153.
78. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000; 106: 253-262.
79. Marks DL, Ling N, Cone RD. Role of central melanocortin system in cachexia. Cancer Res 2001; 61: 1432-1438.
80. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of canceranorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001; 142: 3292-3301.
81. Huang Q, Hruby VJ, Tatro JB. Role of central melanocortins in endotoxin-induced anorexia. Am J Physiol 1999; 276: R864-R871.
82. Marks DL, Butler AA, Brookhart G, Cone RD. Different role of melanocortin receptor subtypes in cachexia. Endocrinology 2003; 144: 1513-1523.
83. Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X, Drisko J, Cashen D, Sebhat I, Patchett AA, Figueroa DJ, DiLella AG, Connolly BM, Weinberg DH, Tan CP, Palyha OC, Pong SS, MacNeil T, Rosenblum C, Vongs A, Tang RYuH, Sailer AW, Fong TM, Huang C, Tota MR, Chang RS, Stearns R, Tamvakopoulos C, Christ G, Drazen DL, Spar BD, Nelson RJ, MacIntyre DE. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA 2002; 99: 11381-11386.
84. Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, Vanderah TW. Ac-nle-c[asp-his-dphe-arg-trp-lys]-nh(2) induces penile erection via brain and spinal melanocortin receptors. Neuroscience 2003; 118: 755-762.
85. Schioth HB, Petersson S, Muceniece R, Szardenings M, Wikberg JE. Deletions of the N-terminal regions of the human melanocortin receptors. FEBS Lett 1997; 410: 223-228.
86. Haskell-Luevano C, Sawyer TK, Trumpp-Kallmeyer S, Bikker JA, Humblet C, Gantz I, Hruby VJ. Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists. Drug Des Discov 1996; 14: 197-211.
87. Yang YK, Dickinson C, Haskell-Luevano C, Gantz I. Molecular basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor. J Biol Chem 1997; 272: 23000-23010.
88. Sawyer TK, Castrucci AM, Staples DJ, Affholter JA, DeVaux AE, Hruby VJ, Hadley ME. Structure-activity relationships of [Nle4, D-Phe7]alpha-MSH. Discovery of a tripeptidyl agonist exhibiting sustained bioactivity. Ann N Y Acad Sci 1993; 680: 597-599.
89. Yang YK, Fong TM, Dickinson CJ, Mao C, Li JY, Tota MR, Mosley R, Van Der Ploeg LH, Gantz I. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry 2000; 39: 14900-14911.
90. Haskell-Luevano C, Cone RD, Monck EK, Wan YP. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. Biochemistry 2001; 40: 6164-6179.
91. Bultman SJ, Michaud EJ, Woychik RP. Molecular characterization of the mouse agouti locus. Cell 1992; 71: 1195-1204.
92. Siracusa LD. The agouti gene: turned on to yellow. Trends Genet 1994; 10: 423-428.
93. Duhl DM, Vrieling H, Miller KA, Wolff GL, Barsh GS. Neomorphic agouti mutations in obese yellow mice. Nat Genet 1994; 8: 59-65.
94. Miller MW, Duhl DM, Vrieling H, Cordes SP, Ollmann MM, Winkes BM, Barsh GS. Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation. Genes Dev 1993; 7: 454-467.
95. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Yowchik RP, Wilkison WO, Cone RD. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994; 371: 799-802.
96. Barsh GS, Ollmann MM, Wilson BD, Miller KA, Gunn TM. Molecular pharmacology of Agouti protein in vitro and in vivo. Ann N Y Acad Sci 1999; 885: 143-152.
97. Willard DH, Bodnar W, Harris C, Kiefer L, Nichols JS, Blanchard S, Hoffman C, Moyer M, Burkhart W, Weiel J. Agouti structure and function: characterization of a potent alpha-melanocyte stimulating hormone receptor antagonist. Biochemistry 1995; 34: 12341-12346.
98. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278: 135-138.
99. Graham M, Shuttre JR, Sarmiento U, Sarosi I, Stark KL. Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet 1997; 17: 273-274.
100. Shutter JR, Graham M, Kinsey AC, Scully S, Luthy R, Stark KL. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev 1997; 11: 593-602.
101. Bagnol D, Lu XY, Kaelin CB, Day HE, Ollmann M, Gantz I, Akil H, Barsh GS, Watson SJ. Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. Journal of Neurosci 1999; 19: RC26.
102. Barsh G, Gunn T, He L, Wilson B, Lu X, Gantz I, Watson S. Neuroendocrine regulation by the Agouti/Agrp-melanocortin system. Endocr Res 2000; 26: 571.
103. Broberger C, Johansen J, Johansson C, Schalling M, Hokfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci USA 1998; 95: 15043-15048.
104. Shen CP, Wu KK, Shearman LP, Camacho R, Tota MR, Fong TM, Van der Ploeg LH. Plasma agouti-related protein level: a possible correlation with fasted and fed states in humans and rats. J Neuroendocrinol 2002; 14: 607-610.
105. Hagan MM, Benoit SC, Rushing PA, Pritchard LM, Woods SC, Seeley RJ. Immediate and prolonged patterns of Agouti-related peptide-(83-132)-induced c-Fos activation in hypothalamic and extrahypothalamic sites. Endocrinology 2001; 142: 1050-1056.
106. Yang YK, Thompson DA, Dickinson CJ, Wilken J, Barsh GS, Kent SB, Gantz I. Characterization of Agouti-related protein binding to melanocortin receptors. Mol Endocrinol 1999; 13: 148-155.
107. Fekete C, Sarkar S, Rand WM, Harney JW, Emerson CH, Bianco AC, Lechan RM. Agouti-related protein (AGRP) has a central inhibitory action on the hypothalamic-pituitary-thyroid (HPT) axis; comparisons between the effect of AGRP and neuropeptide Y on energy homeostasis and the HPT axis. Endocrinology 2002; 143: 3846-3853.
108. Yang YK, Dickinson C, Lai YM, Li JY, Gantz I. Functional properties of an agouti signaling protein variant and characteristics of its cognate radioligand. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1877-R1886.
109. Tota MR, Smith TS, Mao C, MacNeil T, Mosley RT, Van der Ploeg LH, Fong TM. Molecular interaction of Agouti protein and Agouti-related protein with human melanocortin receptors. Biochemistry 1999; 38: 897-904.
110. Quillan JM, Sadee W, Wei ET, Jimenez C, Ji L, Chang JK. A synthetic human Agouti-related protein-(83-132)-NH2 fragment is a potent inhibitor of melanocortin receptor function. Febs Lett 1998; 428: 59-62.
111. Rossi M, Kim MS, Morgan DGA, Small CJ, Edwards CMB, Sunter D, Abusnana S, Goldstone AP, Russell SH, Stanley SA, Smith DM, Yagaloff K, Ghatei MA, Bloom SR. A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 1998; 139: 4428-4431.
112. Willard DH, Bodnar W, Harris C, Kiefer L, Nichols JS, Blanchard S, Hoffman C, Moyer M, Burkhart W, Weiel J, Luther MA, Wilkison WO, Rocque WJ. Agouti structure and function: characterization of a potent alpha-melanocyte stimulating hormone receptor antagonist. Biochemistry 1995; 34: 12341-12346.
113. Young Y, Zeni L, Rosenfeld RD, Stark KL, Rohde MF, Haniu M. Disulfide assignment of the C-terminal cysteine knot of agouti-related protein (AGRP) by direct sequencing analysis. J Pept Res 1999; 54: 514-521.
114. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med 1989; 32: 2555-2561.
115. Bolin KA, Anderson DJ, Trulson JA, Thompson DA, Wilken J, Kent SBH, Gantz I, Millhauser GL. NMR structure of a minimized human agouti related protein prepared by total chemical synthesis. Febs Lett 1999; 451: 125-131.
116. Yang YK, Dickinson CJ, Zeng Q, Li JY, Thompson DA, Gantz I. Contribution of melanocortin receptor exoloops to Agouti-related protein binding. J Biol Chem 1999; 274: 14100-14106.
117. Yang YK, Chen M, Lai Y, Gantz I, Yagmurlu A, Georgeson KE, Harmon CM. Molecular determination of Agouti-related protein (AGRP) binding to human melanocortin-4 receptor. Mol Pharmacol 2003; 64: 94-103.
118. Gunn TM, Barsh GS. Mahogany/attractin: en route from phenotype to function. Trends Cardiovasc Med 2000; 10: 76-81.
119. Barsh G, Gunn T, He L, Schlossman S, Duke-Cohan J. Biochemical and genetic studies of pigment-type switching. Pigment Cell Res 2000; 8: 48-53.
120. Nagle DL, McGrail SH, Vitale J, Woolf EA, Dussault BJ Jr, DiRocco L, Holmgren L, Montagno J, Bork P, Huszar D, Fairchild-Huntress V, Ge P, Keilty J, Ebeling C, Baldini L, Gilchrist J, Burn P, Carlson GA, Moore KJ. The mahogany protein is a receptor involved in suppression of obesity. Nature 1999; 398: 148-152.
121. Gunn TM, Azarani A, Kim PH, Hyman RW, Davis RW, Barsh GS. Identification and preliminary characterization of mouse Adam33. BMC Genet 2002; 3: 2.
122. Lu X, Gunn TM, Shieh K, Barsh GS, Akil H, Watson SJ. Distribution of Mahogany/Attractin mRNA in the rat central nervous system. FEBS Lett 1999; 462: 101-107.
123. Barsh GS, He L, Gunn TM. Genetic and biochemical studies of the Agouti-attractin system. J Recept Signal Transduct Res 2002; 22: 63-77.
124. He L, Gunn TM, Bouley DM, Lu XY, Watson SJ, Schlossman SF, Duke-Cohan JS, Barsh GS. A biochemical function for attractin in agouti-induced pigmentation and obesity. Nat Genet 2001; 27: 40-47.
125. Gunn TM, Inui T, Kitada K, Ito S, Wakamatsu K, He L, Bouley DM, Serikawa T, Barsh GS. Molecular and phenotypic analysis of Attractin mutant mice. Genetics 2001; 158: 1683-1695.
126. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-777.
127. Rapraeger AC, Ott VL. Molecular interactions of the syndecan core proteins. Curr Opin Cell Biol 1998; 10: 620-628.
128. Woods A, Couchman JR. Syndecans: synergistic activators of cell adhesion. Trends Cell Biol 1998; 8: 189-192.
129. Reizes O, Lincecum J, Wang Z, Goldberger O, Huang L, Kaksonen M, Ahima R, Hinkes MT, Barsh GS, Rauvala H, Bernfield M. Transgenic expression of syndecan-1 uncovers a physiological control of feeding behavior by syndecan-3. Cell 2001; 106: 105-116.